Clinical collaborations drive cancer immunotherapy


A joint clinical trial agreement between Merck & Co and Pfizer is the latest in what is becoming a rather tangled web of tie-ups between companies with cancer drugs that harness patients’ immune systems. These immuno-oncology drugs stop tumours from disguising themselves from natural defence mechanisms, but work better when more than one of these pathways are blocked simultaneously, or in combination with chemotherapy agents that will attack tumours directly. Hence, companies are touting their products as widely as possible to counterparts with complementary drugs.

This agreement will see Merck & Co’s anti-programmed death-ligand 1 (PD-L1) antibody, pembrolizumab, tested with Pfizer’s lung cancer drug Xalkori (crizotinib) in a Phase 1b trial. Trials of pembrolizumab and a second Pfizer drug at a much earlier developmental stage have also been agreed.

Merck & Co has already signed up several other partners to test combinations of their drugs with pembrolizumab. In February, the company revealed plans involving yet another Pfizer drug – Inlyta (axitinib) for renal cell carcinoma – as well as Amgen’s cancer-killing virus talimogene laherparepvec, and Incyte’s indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360.

Incyte itself has struck deals to run trials of INCB24360 with Roche subsidiary Genentech’s anti-PD-L1 antibody MPDL3280A; two antibody treatments from Bristol-Myers Squibb (BMS) (nivolumab and ipilimumab); and MEDI4736, an anti-PD-L1 antibody from AstraZeneca’s biological drugs subsidiary MedImmune.

In turn, several of those drugs are involved in combination trials elsewhere: BMS and Celgene are investigating nivolumab in combination with Abraxane – a version of blockbuster cancer drug Taxol (paclitaxel) bound to the blood protein albumin; and MedImmune has signed up with antibody drugmakers Advaxis in the US and Kyowa Hakko Kirin of South Korea.


Related Content

Pharma queues up for checkpoint inhibitor collaborations

3 July 2015 Business

news image

Combinations of different firms’ drugs seek to reap immuno-oncology’s benefits

Celgene backs immunotherapy with Juno collaboration

8 July 2015 Business

news image

$1bn investment in 10-year CAR-T cell partnership for cancer treatments

Most Read

US government science institute's one time police chief linked to campus meth lab

31 July 2015 News and Analysis

news image

Explosion injuring a member of the National Institute of Standards and Technology's security force uncovered methamphetamine ...

Antifreeze polymer protects cells as they thaw

29 July 2015 Research

news image

Simple synthetic polymer found to enhance cryopreservation of red blood cells by inhibiting ice crystal growth

Most Commented

(–)-Jiadifenolide

27 July 2015 Organic Matter

news image

BRSM wonders what makes a route so good it becomes the last total synthesis of a complex target

Butterfly population collapse prompts lawsuit against EPA

5 March 2015 News and Analysis

news image

US agency criticised for failing to investigate link between glyphosate and the dwindling monarch butterfly population